OralParenteralDosed ingredient Cosmetic cross-reference

Niacinamide

CAS 98-92-0

Niacinamide (CAS 98-92-0) is a Phase 4 pharmaceutical compound with 13 bioactivity targets and 3,772 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

3,772

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Niacinamide

CAS Number

98-92-0

UNII

25X51I8RD4

InChIKey

DFPAKSUCGFBDDF-UHFFFAOYSA-N

ChEMBL ID

CHEMBL1140

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoralparenteral

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1140 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE NLM DailyMed 2 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

Product	Ingredient	Active Moiety	Effective
AOAO Acne Buster Salicylic Acid Drying Serum	NIACINAMIDE 25X51I8RD4	NIACINAMIDE	20260506
PEGO Acne Buster Salicylic Acid Drying Serum	NIACINAMIDE 25X51I8RD4	NIACINAMIDE	20260505

SOURCE EMBL-EBI ChEMBL 18 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	37936.90037037037 nM	53	-
-	AC50	28315.793939393938 nM	33	-
-	Potency	6694.442857142857 nM	7	-
-	Ki	8000000 nM	1	-
Hydroxycarboxylic acid receptor 2 GPCR	-	-	-	Homo sapiens
Hydroxycarboxylic acid receptor 3 GPCR	-	-	-	Homo sapiens
Nicotinamide N-methyltransferase Enzyme	-	-	-	Homo sapiens
Nicotinate-nucleotide pyrophosphorylase [carboxylating] Enzyme	-	-	-	Homo sapiens
NAD-dependent protein deacetylase sirtuin-1 Enzyme	IC50	4.3	-	Homo sapiens
NAD-dependent protein deacetylase sirtuin-2 Enzyme	IC50	5.92	-	Homo sapiens
Fatty-acid amide hydrolase 1 Enzyme	IC50	5.48	-	Rattus norvegicus
NAD-dependent deacetylase HST2 Enzyme	IC50	4.04	-	Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
NAD-dependent deacetylase sirtuin 3 Enzyme	IC50	4.85	-	Homo sapiens
NAD-dependent protein deacylase sirtuin-5, mitochondrial Enzyme	IC50	4.33	-	Homo sapiens
Putative silent information regulator 2 Unclassified	IC50	4.4	-	Leishmania infantum
Sterile alpha and TIR motif-containing protein 1 Unclassified	IC50	4.36	-	Homo sapiens
NAD-dependent protein deacetylase Unclassified	IC50	4.64	-	Schistosoma mansoni
NAD-dependent protein deacetylase Unclassified	IC50	4.41	-	Leishmania infantum

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pemphigus	5401	2658.86	10034280
Systemic lupus erythematosus	5715	2552.447	10042945
Glossodynia	4952	2232.948	10018388
Hand deformity	4328	1885.404	10061194
Arthropathy	5581	1767.721	10003285
Rheumatoid arthritis	5927	1733.417	10039073
Alopecia	6759	1665.411	10001760
Abdominal discomfort	6908	1630.236	10000059
Wound	4179	1532.311	10052428
Maternal exposure during pregnancy	4726	1475.488	10071408
Toxicity to various agents	998	1394.542	10070863
Completed suicide	163	1350.074	10010144
Synovitis	4239	1307.42	10042868
Joint swelling	6417	1225.877	10023232
Swelling	5521	1183.907	10042674
Contraindicated product administered	4738	1183.88	10078504
Anti-cyclic citrullinated peptide antibody positive	2939	1172.573	10068798
Pain	12161	1125.94	10033371
Discomfort	3821	1123.857	10013082
Pericarditis	3237	1100.752	10034484
Infusion related reaction	5405	1091.388	10051792
Drug abuse	120	928.865	10013654
Arthralgia	9650	872.775	10003239
Death	3383	862.908	10011906
Drug interaction	1487	848.481	10013710
Duodenal ulcer perforation	2093	742.637	10013849
Helicobacter infection	2161	717.988	10054263
Rheumatoid factor positive	1968	707.312	10039080
Psoriatic arthropathy	2238	671.467	10037162
Hepatic enzyme increased	3860	650.739	10060795
Musculoskeletal stiffness	3672	634.443	10052904
Exposure during pregnancy	2972	632.244	10073513
Intentional overdose	114	605.491	10022523
Drug intolerance	5236	593.246	10061822
Product use issue	4366	581.828	10076309
Acute kidney injury	2533	555.445	10069339
Therapeutic product effect decreased	3542	538.665	10082201
Febrile neutropenia	810	532.51	10016288
Overdose	683	436.009	10033295
Nasopharyngitis	4330	426.84	10028810
Knee arthroplasty	1264	391.913	10023469
Suicide attempt	159	382.654	10042464
Treatment failure	3534	378.881	10066901
Disease progression	887	377.161	10061818
Hypersensitivity	4568	372.754	10020751
Hip arthroplasty	1127	370.04	10020096
Impaired healing	1924	343.737	10021519
Rheumatic fever	970	326.297	10039054
Foetal exposure during pregnancy	1800	326.031	10071404
Cardiac arrest	620	323.6	10007515

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
niacinamide	7405	SU	MTHSPL
Niacinamide	7405	SU	MTHSPL
NIACINAMIDE	7405	SU	MTHSPL
niacinamide	7405	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Niacinamide used for in pharmaceutical contexts?

Niacinamide (CAS 98-92-0) appears in DailyMed active-ingredient label rows, including AOAO Acne Buster Salicylic Acid Drying Serum, PEGO Acne Buster Salicylic Acid Drying Serum.

What are the known adverse events for Niacinamide?

Niacinamide has 3,772 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Glossodynia, Hand deformity, Arthropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Niacinamide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Niacinamide with EU status "permitted".

What clinical phase is Niacinamide in?

Niacinamide is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Niacinamide?

Niacinamide has 18 bioactivity rows in this page query. Rendered target entries include Hydroxycarboxylic acid receptor 2, Hydroxycarboxylic acid receptor 3, Nicotinamide N-methyltransferase, Nicotinate-nucleotide pyrophosphorylase [carboxylating], NAD-dependent protein deacetylase sirtuin-1.